论文部分内容阅读
为了弄清癌患者的免疫抑制状态,近年来,免疫抑制酸蛋白(IAP)和过氯酸可溶性糖蛋白(ASP)引起大家的注意。作者对于头颈部癌患者测定其血清中的 IAP 和ASP 的浓度,并对于治疗效果判定、复发等进行研究,报告如下。测定方法:血清中的 IAP,用 IAP 感光板,以一元放射免疫扩散法(SRID 法)进行判定。把5微升被检血清在37℃下进行48小时反应,根据沉降轮的直径算出 IAP 浓度。血清中的 ASP 用比色法(ASPRO 法)进行测定。IAP 在500ug/ml 以上,ASP 在150(?)/dl 以上判定为阳性。结果:对于8例上颌癌、4例唾液腺癌、5例舌癌,3例牙龈癌、4例口底癌、1例下颌骨转移癌的血清中 IAP 和 ASP 的变化
In order to understand the immunosuppressive state of cancer patients, immunosuppressive acid protein (IAP) and perchloric acid soluble glycoprotein (ASP) have attracted attention in recent years. The authors determined the concentration of IAP and ASP in serum of patients with head and neck cancer, and conducted studies on the therapeutic effect determination and recurrence. The report is as follows. Assay method: IAP in serum was determined using a unipolar radioimmunoassay (SRID) method using an IAP plate. Five microliters of the test serum was reacted at 37°C for 48 hours, and the IAP concentration was calculated from the diameter of the settling wheel. The ASP in serum was determined by the colorimetric method (ASPRO method). The IAP was above 500 ug/ml and ASP was positive above 150 (?)/dl. Results: Changes in serum IAP and ASP in 8 cases of maxillary carcinoma, 4 cases of salivary gland cancer, 5 cases of tongue cancer, 3 cases of gingival carcinoma, 4 cases of floor cancer, 1 case of metastatic carcinoma of mandible